Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

AOD-9604vsTirzepatide

A modified fragment of human growth hormone that targets fat cells for breakdown without affecting blood sugar or muscle growth—your metabolism's precision tool.

The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.

Weight ManagementWeight Management

At a Glance

Quick
comparison

Dose Range

AOD-9604

250–500 mcg

Tirzepatide

2.5–15 mg

Frequency

AOD-9604

Once daily

Tirzepatide

Once weekly

Administration

AOD-9604

Subcutaneous injection

Tirzepatide

Subcutaneous injection

Cycle Length

AOD-9604

8-12 weeks

Tirzepatide

Ongoing/indefinite

Onset Speed

AOD-9604

Gradual (3-4 weeks)

Tirzepatide

Moderate (1-2 weeks)

Evidence Level

AOD-9604

Moderate human trials (Phase 1-2)

Tirzepatide

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit
ratings

AOD-9604
Tirzepatide

Fat Targeting

AOD-960492%
Tirzepatide0%

Safety Profile

AOD-960495%
Tirzepatide0%

Joint Support

AOD-960478%
Tirzepatide0%

Weight Loss

AOD-96040%
Tirzepatide99%

Appetite Control

AOD-96040%
Tirzepatide97%

Blood Sugar Control

AOD-96040%
Tirzepatide96%

Technical Data

Compound
specifications

AOD-9604

Molecular Formula

C78H123N23O23S2

Molecular Weight

1815.1 g/mol

Half-Life

~3-4 minutes (plasma)

Bioavailability

High (subcutaneous)

CAS Number

221231-10-3

Tirzepatide

Molecular Formula

C225H348N48O68

Molecular Weight

4813.45 g/mol

Half-Life

Approximately 5 days (120 hours)

Bioavailability

~80% (subcutaneous)

CAS Number

2023788-19-2

Protocols

Dosing
tiers

AOD-9604

starting

250 mcg

Once daily

2-4 weeks

Begin here to assess tolerance. Inject on an empty stomach, ideally in the morning before food or exercise.

standard

300-400 mcg

Once daily

8-12 weeks

The most commonly used dose range for consistent fat metabolism support. Best taken fasted in the morning.

advanced

500 mcg

Once daily

8-12 weeks

Maximum dose used in clinical studies. Some users split into two 250mcg doses (morning and before bed).

Tirzepatide

starting

2.5 mg

Once weekly

4 weeks

This introductory dose helps your body adjust to the medication and minimizes GI side effects. Don't expect much weight loss yet—this phase is all about building tolerance. Think of it as your body's training wheels period.

standard

5-10 mg

Once weekly

4+ weeks at each dose

After 4 weeks at 2.5mg, increase to 5mg. Stay here for at least 4 weeks, then move to 7.5mg, then 10mg. This gradual climb reduces side effects while ramping up the weight loss. Most people start seeing serious results at 5-10mg doses.

advanced

12.5-15 mg

Once weekly

Ongoing/maintenance

The 15mg dose delivers maximum weight loss—averaging over 20% of body weight in trials. Continue increasing by 2.5mg every 4 weeks until reaching 15mg or your optimal maintenance dose. This is where the jaw-dropping results happen.

Applications

Best
suited for

AOD-9604

Targeted Fat Loss

AOD-9604 shines when you want to target stubborn fat deposits. It works by mimicking how growth hormone breaks down fat, but without the side effects of actual HGH. Think of it as a smart missile that targets fat cells specifically.

Body Recomposition

Perfect for those who want to lose fat while maintaining muscle. Unlike many fat loss compounds, AOD-9604 doesn't affect muscle tissue or mess with your blood sugar levels—it's laser-focused on fat metabolism.

Metabolic Enhancement

Ideal for boosting your metabolism naturally. AOD-9604 increases fat oxidation (your body's ability to burn fat for fuel) without the jittery stimulant effects of caffeine or other thermogenics.

Joint Health Support

Emerging research shows AOD-9604 may help repair cartilage and support joint health. Studies in osteoarthritis models show it can reduce cartilage damage, making it a dual-purpose peptide for active individuals.

Metabolically Safe Fat Loss

Unlike many weight loss compounds, AOD-9604 doesn't raise blood sugar, doesn't affect insulin, and doesn't stimulate cell growth. It's one of the gentlest approaches to enhancing fat metabolism available.

Tirzepatide

People Who Want Maximum Weight Loss Results

If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close.

Those Who Haven't Succeeded with Semaglutide

Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss.

People with Type 2 Diabetes Needing Aggressive Control

Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health.

Individuals Looking to Transform Their Relationship with Food

Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you.

Safety Profile

Side
effects

AOD-9604

Common

  • Injection site reactions
  • Mild headache
  • Flushing or warmth

Uncommon

  • Fatigue
  • Dizziness

Serious

  • Allergic reaction

Tirzepatide

Common

  • Nausea
  • Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Thinning (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Research Status

Safety
& evidence

AOD-9604

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Not FDA approved

Safety Overview

AOD-9604 has been studied in multiple human clinical trials involving thousands of participants. The safety profile is notably clean—it doesn't affect blood sugar, insulin levels, or cause the typical side effects of growth hormone. Phase 2 trials showed it was well-tolerated even at doses higher than typically used. The most common side effects are mild and injection-site related.

Contraindications

  • xPregnancy or breastfeeding
  • xActive cancer or history of cancer
  • xKnown allergy to growth hormone-derived peptides
  • xChildren and adolescents

Tirzepatide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. The FDA approved it after thorough safety review. While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes.

Contraindications

  • xPersonal or family history of medullary thyroid carcinoma (MTC)
  • xMultiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • xHistory of serious allergic reaction to tirzepatide or any GLP-1/GIP medication
  • xCurrent or recent pancreatitis
  • xPregnancy or planning to become pregnant

Decision Guide

Which is
right for you?

Choose AOD-9604 if...

  • Fat loss
  • Body composition improvement
  • Metabolic support
  • Joint health support

Choose Tirzepatide if...

  • Maximum weight loss results
  • Long-term obesity management
  • Type 2 diabetes control
  • Metabolic health improvement
Peptide ProAOD-9604 vs Tirzepatide — Peptide Comparison | Peptide Initiative